Previous 10 | Next 10 |
NEW YORK, June 16, 2020 (GLOBE NEWSWIRE) -- Bionic Sight, LLC announced today that it has dosed the first patient in the Company’s Phase 1/2 clinical trial of BS01, an optogenetic gene therapy for patients with Retinitis Pigmentosa. This is an important step toward bringing BS01 forw...
Mobile vision testing unit enables X-linked retinitis pigmentosa and achromatopsia clinical trial patients to maintain important scheduled study assessments during COVID-19 pandemic GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 15, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies C...
Applied Genetic Reports Positive Preclinical Data for Eye Disorder Treatment Applied Genetic Technologies Corporation (AGTC) announced the results for its clinical trial related to X-Linked retinitis pigmentosa. The data provided the basis for determining the starting dose and the vector...
Applied Genetic Technologies ( AGTC +4.0% ) announces the publication in Human Gene Therapy of preclinical data supporting the rationale of the vector it is using in its gene therapy for patients with X-linked retinitis pigmentosa (XLRP), an inherited disorder characterized by progre...
- Administration of AGTC’s proprietary adeno-associated virus (AAV) vectors expressing variants of the RPGR gene corrected early markers of disease and provided evidence of a rescue effect in an animal model of XLRP, with a favorable safety profile - GAINESVILLE...
Applied Genetic Technologies Corporation (AGTC) Q3 2020 Results Conference Call May 13, 2020 08:00 AM ET Company Participants Sue Washer - CEO Matt Feinsod - EVP of Global Strategy and Development Mark Shearman - CSO Bill Sullivan - CFO Conference Call Participants Jim...
The following slide deck was published by Applied Genetic Technologies Corporation in conjunction with their 2020 Q3 earnings Read more ...
Applied Genetic (NASDAQ: AGTC ): Q3 GAAP EPS of -$0.50 beats by $0.05 . More news on: Applied Genetic Technologies Corporation, Earnings news and commentary, Healthcare stocks news, , Read more ...
- Company on track to provide multiple data readouts for XLRP and ACHM clinical programs in 2H 2020 - - Company on track for End of Phase 2 meeting in Q2 2020 - - Company sees minimal COVID-19 impact to date - - Company to host conference call and webcast today at 8:00am ET - ...
SAN DIEGO, May 12, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced preclinical results from the company’s gene therapy collaboration with Applied Genetic T...
News, Short Squeeze, Breakout and More Instantly...
Applied Genetic Technologies Corporation Company Name:
AGTC Stock Symbol:
NASDAQ Market:
Applied Genetic Technologies Corporation Website:
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), announced today that a portfolio company of Syncona Limited (LON: SYNC) (“Syncona”) has exte...
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), President and Chief Executive Officer, Sue Washer, reminds AGTC stockholders: A Syncona Limited portfolio company has commenced a tender offer to purcha...
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), President and Chief Executive Officer, Sue Washer, reminds AGTC stockholders: A Syncona Limited portfolio company has commenced a tender offer to purcha...